Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13356456 | 0.84 | ACP1 (0.54) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL6901262 | 0.82 | PTGES (0.52) | RAB9AMAPTALDH1A1HTTNPC1 | |
| SCHEMBL3223775 | 0.78 | MAPT (0.71) | RAB9AMAPTALDH1A1GAAHTT | |
| SCHEMBL11714214 | 0.76 | APP (0.71) | RAB9AMAPTALDH1A1GAANPC1 | |
| SCHEMBL13356419 | 0.75 | MAPK1 (0.50) | RAB9AMAPTALDH1A1NPC1MEN1 | |
| SCHEMBL16488065 | 0.74 | RAB9A (0.62) | RAB9AMAPTALDH1A1GAAHTT | |
| SCHEMBL21131515 | 0.74 | MAPT (0.63) | RAB9AMAPTALDH1A1GAAHTT | |
| SCHEMBL17682914 | 0.73 | RAB9A (0.61) | RAB9AMAPTALDH1A1GAAHTT | |
| SCHEMBL11711833 | 0.73 | NR4A1 (0.62) | RAB9AMAPTALDH1A1GAAHTT | |
| SCHEMBL29408378 | 0.73 | RAB9A (0.61) | RAB9AMAPTALDH1A1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1635890-A | Neuroprotective 2-pyridinamine compositions and related methods | ORTHO MCNEIL PHARM INC (US) | 2005-07-06 | — | — | CN | claimed |
| JP-2004510707-A | — | — | 2004-04-08 | — | — | JP | claimed |
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | GRANT ELFRIDA R (US) | 2003-12-04 | — | — | US | claimed |
| EP-1317266-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | claimed |
| WO-2002011724-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| CN-1635890-A | Neuroprotective 2-pyridinamine compositions and related methods | ORTHO MCNEIL PHARM INC (US) | 2005-07-06 | — | — | CN | disclosed |
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | GRANT ELFRIDA R (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1317266-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002011724-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | AIFM1, CASP5, CASP2 | RAB9A 3094/4885MAPT 403/4885ALDH1A1 1986/4885 |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | AIFM1, CASP5, CASP2 | RAB9A 3094/4885MAPT 403/4885ALDH1A1 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.